CPC A61K 47/06 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 39/3955 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); C07K 16/22 (2013.01); C07K 16/241 (2013.01); C07K 16/2839 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); A61K 38/00 (2013.01)] | 24 Claims |
1. A liquid pharmaceutical formulation for injection comprising:
(i) an antibody;
(ii) about 0.1 M to about 0.4 M of 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) or a pharmaceutically acceptable salt thereof; and
(iii) a pharmaceutically acceptable solvent;
wherein the liquid pharmaceutical formulation, when in a volume suitable for injection, has an absolute viscosity of from about 1 cP to about 100 cP at 25° C. as measured using a cone and plate viscometer or a microfluidic viscometer; and the absolute viscosity of the liquid pharmaceutical formulation is less than an absolute viscosity of a control composition comprising the antibody and the pharmaceutically acceptable solvent but without the EMMC; and
wherein the absolute viscosity is an extrapolated zero-shear viscosity.
|